Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/18/2019 06/19/2019 06/20/2019 06/21/2019 06/24/2019 Date
47.79(c) 48.61(c) 48.89(c) 49.34(c) 45.9 Last
11 523 657 8 720 820 9 441 626 14 979 313 20 566 394 Volume
-0.87% +1.72% +0.58% +0.92% -6.97% Change
More quotes
Financials (USD)
Sales 2019 24 127 M
EBIT 2019 6 842 M
Net income 2019 6 753 M
Finance 2019 4 497 M
Yield 2019 3,32%
Sales 2020 25 071 M
EBIT 2020 7 203 M
Net income 2020 6 964 M
Finance 2020 7 593 M
Yield 2020 3,40%
P/E ratio 2019 12,32
P/E ratio 2020 11,46
EV / Sales2019 3,16x
EV / Sales2020 2,92x
Capitalization 80 707 M
More Financials
Company
Bristol-Myers Squibb Company specializes in the development, manufacturing and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - cancers (33.5%); - cardiovascular diseases (23.5%); - viral diseases (19.8%); - immune diseases (11.9%); - psychiatric... 
Sector
Pharmaceuticals
Calendar
07/03Ex-dividend day for
More about the company
Surperformance© ratings of Bristol-Myers Squibb Compa
Trading Rating : Investor Rating :
More Ratings
Latest news on BRISTOL-MYERS SQUIBB COMPA
12:05pBRISTOL MYERS SQUIBB : Myers' Celgene Deal Can Still Be a Winner -- Heard on the..
DJ
12:02pMARKETS RIGHT NOW : Stocks trade mixed on Wall Street
AQ
11:55aBRISTOL MYERS SQUIBB : Myers plans to divest Celgene's psoriasis drug
RE
11:53aBRISTOL MYERS SQUIBB : Myers plans to divest Celgene's psoriasis drug, shares sl..
RE
10:16aBRISTOL MYERS SQUIBB : Stocks start the week sideways ahead of trade talks
AQ
09:23aStocks to Watch: Caesars, Bristol-Myers, Carnival, FedEx, and More
DJ
08:39aBRISTOL MYERS SQUIBB : Myers to Shed Otezla, Carving Path for Celgene Deal
DJ
08:20aBRISTOL MYERS SQUIBB : Current report filing
PU
08:04aBRISTOL MYERS SQUIBB CO : Other Events, Financial Statements and Exhibits (form ..
AQ
07:00aBRISTOL MYERS SQUIBB : Provides Update on Pending Merger with Celgene
BU
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPA
More recommendations
Stock Trading Strategies
BRISTOL-MYERS SQUIBB COMPANY - 04/08
Underpinned by a support level
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
12:05pBRISTOL MYERS SQUIBB : Myers' Celgene Deal Can Still Be a Winner -- Heard on the..
DJ
11:55aBRISTOL MYERS SQUIBB : Myers plans to divest Celgene's psoriasis drug
RE
11:53aBRISTOL MYERS SQUIBB : Myers plans to divest Celgene's psoriasis drug, shares sl..
RE
09:24aAbbVie Says FDA Lifts Partial Hold on Phase 3 Trial
DJ
08:39aBRISTOL MYERS SQUIBB : Myers to Shed Otezla, Carving Path for Celgene Deal
DJ
More sector news : Pharmaceuticals - NEC
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 56,3 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Johanna Mercier President & Head-US Commercial
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-5.08%75 440
JOHNSON & JOHNSON10.10%348 981
PFIZER0.05%233 072
ROCHE HOLDING LTD.13.87%227 848
NOVARTIS21.31%220 893
MERCK AND COMPANY10.68%206 641